C83.1

Mantle cell lymphoma

A clinico-pathological entity reflecting the multiple polyps throughout the gastrointestinal tract created as a result of involvement by a non-hodgkin lymphoma. Typically, mantle cell lymphomas involving the gastrointestinal tract give rise to multifocal lymphomatous polyposis. Importantly, other histologic subtypes of non-hodgkin lymphoma can also produce this clinico-pathological entity. who, 2000)

A form of non-hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-hodgkin lymphomas in the United States and europe. The majority of mantle-cell lymphomas are associated with a t 11;14) translocation resulting in overexpression of the cyclin d1 gene genes, bcl-1).

A group of cancers of the lymphoid system, including acute lymphoblastic leukemia, b-cell lymphoma, burkitt’s lymphoma, diffuse cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, mantle cell lymphoma, mycosis fungoides, post-transplantation lymphoproliferative disorder, small non-cleaved cell lymphoma, and t-cell lymphoma.

An aggressive fast-growing) type of b-cell non-hodgkin lymphoma that usually occurs in middle-aged or older adults. It is marked by small- to medium-size cancer cells that may be in the lymph nodes, spleen, bone marrow, blood, and gastrointestinal system.

An aggressive, usually diffuse non-hodgkin lymphoma composed of small to medium sized b-lymphocytes centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-hodgkin lymphoma. The vast majority of cases express the t 11;14) q13;q32) resulting in the rearrangement of the bcl-1 gene and the overexpression of cyclin d1 mrna.

Any of a group of malignant tumors of lymphoid tissue that differ from hodgkin disease, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant reed-sternberg cells, a characteristic of hodgkin’s disease.

Any of a large group of cancers of lymphocytes white blood cells). Nhls can occur at any age and are often marked by lymph nodes that are larger than normal, fever, and weight loss. There are many different types of nhl. These types can be divided into aggressive fast-growing) and indolent slow-growing) types, and they can be formed from either b-cells or t-cells. B-cell nhls include burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma cll/sll), diffuse large b-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor b-lymphoblastic lymphoma, and mantle cell lymphoma. T-cell nhls include mycosis fungoides, anaplastic large cell lymphoma, and precursor t-lymphoblastic lymphoma. Lymphomas that occur after bone marrow or stem cell transplantation are usually b-cell nhls. Prognosis and treatment depend on the stage and type of disease.

Characterized by malignant lymphomas; clinically similar to hodgkin’s disease, except that the lymphomas seen in this disease are initially more widespread; most common manifestation is painless enlargement of one or more peripheral lymph nodes.

Distinct from hodgkin lymphoma both morphologically and biologically, non-hodgkin lymphoma nhl) is characterized by the absence of reed-sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. Nhl is clinically classified as indolent, aggressive, or having a variable clinical course. Nhl can be of b-or t-/nk-cell lineage.

C83.1 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.

This is the American ICD-10-CM version of C83.1 – other international versions of ICD-10 C83.1 may differ.